JPMorgan Chase & Co. Sells 512,299 Shares of Qiagen N.V. $QGEN

JPMorgan Chase & Co. trimmed its holdings in Qiagen N.V. (NYSE:QGEN) by 40.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 740,649 shares of the company’s stock after selling 512,299 shares during the period. JPMorgan Chase & Co. owned 0.33% of Qiagen worth $33,092,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. United Services Automobile Association acquired a new stake in Qiagen during the 1st quarter valued at $239,000. Envestnet Asset Management Inc. raised its position in shares of Qiagen by 26.6% in the second quarter. Envestnet Asset Management Inc. now owns 425,396 shares of the company’s stock valued at $20,439,000 after purchasing an additional 89,301 shares during the period. Atria Investments Inc lifted its stake in shares of Qiagen by 2.9% during the 2nd quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after buying an additional 218 shares during the last quarter. Amalgamated Bank boosted its holdings in shares of Qiagen by 1.8% during the 2nd quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock worth $565,000 after buying an additional 209 shares during the period. Finally, Simon Quick Advisors LLC acquired a new position in Qiagen in the 2nd quarter valued at about $208,000. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Stock Performance

Qiagen stock opened at $49.81 on Friday. The company has a quick ratio of 3.31, a current ratio of 3.90 and a debt-to-equity ratio of 0.44. The stock has a market cap of $10.52 billion, a PE ratio of 24.71, a P/E/G ratio of 2.39 and a beta of 0.67. Qiagen N.V. has a 12-month low of $39.61 and a 12-month high of $57.81. The business’s 50-day moving average price is $50.01 and its two-hundred day moving average price is $49.37.

Qiagen (NYSE:QGEN) last posted its earnings results on Thursday, February 5th. The company reported $0.62 EPS for the quarter, topping analysts’ consensus estimates of $0.61 by $0.01. The firm had revenue of $540.42 million during the quarter, compared to analysts’ expectations of $528.53 million. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.61 earnings per share. As a group, analysts expect that Qiagen N.V. will post 2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on QGEN shares. Barclays set a $58.00 price objective on Qiagen and gave the stock an “overweight” rating in a report on Friday, February 6th. Citigroup reduced their price target on Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research note on Friday, February 6th. JPMorgan Chase & Co. increased their price objective on Qiagen from $55.00 to $60.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a report on Monday, December 29th. Finally, TD Cowen restated a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Four investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $55.20.

Qiagen News Roundup

Here are the key news stories impacting Qiagen this week:

• Positive Sentiment: DWS Investment disclosed a 2.76% voting stake in Qiagen — a notable institutional position that can lend support to the share price, raise confidence among other investors and prompt speculation about engagement or strategic influence. DWS Investment Discloses 2.76% Voting Stake in Qiagen
• Positive Sentiment: Reports show large volumes of Qiagen call options were purchased, indicating bullish positioning or short-term speculative interest that can amplify upward moves in the stock and attract momentum traders. Investors Buy Large Volume of Qiagen Call Options (NYSE:QGEN)
• Negative Sentiment: Zacks Research reduced EPS estimates across multiple near-term quarters and trimmed FY2026 and FY2027 forecasts (FY2026 cut from $2.57 to $2.51; FY2027 trimmed to $2.81 from $2.85), and lowered several quarterly estimates (Q1–Q3 2026 and Q2–Q3 2027). Those downgrades signal weaker near-term earnings growth expectations and could limit upside if revisions continue.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.